Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion InfusionsDHA:ORIONINFU -6.34%76 EV-to-EBITDA is 53.95 as of Aug. 17, 2026, which is 167% above its 10-year median of 20.18. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 76/100 and a GF Value™ of BDT314.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 734 Drug Manufacturers companies, Orion Infusions ranks worse than 89.51% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Orion Infusions's enterprise value is BDT5,241.7 Mil.
Orion Infusions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was BDT97.2 Mil. Therefore, Orion Infusions's EV-to-EBITDA for today is 53.95.
The historical rank and industry rank for Orion Infusions's EV-to-EBITDA or its related term are showing as below:
DHA:ORIONINFU'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 13.92 Med: 20.18 Max: 178.73
Current: 53.94
During the past 13 years, the highest EV-to-EBITDA of Orion Infusions was 178.73. The lowest was 13.92. And the median was 20.18.
DHA:ORIONINFU's EV-to-EBITDA is ranked worse than 89.51% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs DHA:ORIONINFU: 53.94
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Orion Infusions's PE Ratio (TTM) for today is calculated as:
Orion Infusions's share price for today is BDT243.60.
Orion Infusions's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT1.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Orion Infusions's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONINFU vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orion Infusions's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Infusions EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Infusions's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Orion Infusions's EV-to-EBITDA falls into.
Orion Infusions's current Enterprise Value is BDT5,241.7 Mil.
Orion Infusions's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT97.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Infusions (DHA:ORIONINFU) has a EV-to-EBITDA of 53.95 as of Aug. 17, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Orion Infusions. This is 167% above median its historical median of 20.18. Over the past decade, Orion Infusions' EV-to-EBITDA has ranged from 13.92 to 178.73. According to the industry distribution chart, Orion Infusions ranks #657 out of 734 companies in the Drug Manufacturers industry, placing it in the top 89.5%.
Is Orion Infusions' EV-to-EBITDA too high?
Orion Infusions' current EV-to-EBITDA of 53.95 is 167% above median its 10-year median of 20.18. Over the past 10 years, this metric has ranged from a low of 13.92 to a high of 178.73. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Orion Infusions' value of 53.95 is 304.9% above this industry median. Based on the distribution chart, Orion Infusions ranks #657 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Orion Infusions has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Orion Infusions ranks #657 out of 734 companies for EV-to-EBITDA. This places Orion Infusions in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. Orion Infusions' value of 53.95 is 304.9% above this benchmark. Historically, Orion Infusions' own EV-to-EBITDA has ranged from 13.92 to 178.73 over the past decade. While the company's 10-year median is 20.18 vs. the industry median of 13.33, Orion Infusions has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Infusions's current EV-to-EBITDA of 53.95 is 304.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Orion Infusions. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Infusions's current EV-to-EBITDA is 53.95, which is 167% above median its own 10-year median of 20.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Modestly Undervalued. The stock's GF Value™ is BDT314.14, compared to a current price of BDT243.60 — trading 22.5% below its estimated fair value. The current EV-to-EBITDA is 53.95, which is 167% above median its 10-year median of 20.18 and 304.9% above the Drug Manufacturers industry median of 13.33. Orion Infusions' overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current EV-to-EBITDA is 53.95 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued.
The current stock price of BDT243.60 is trading 22.5% below its estimated GF Value™ of BDT314.14.
GuruFocus considers Orion Infusions to be Modestly Undervalued.
Key valuation signals for DHA:ORIONINFU:
EV-to-EBITDA: 53.95 (167% above median its 10-year median of 20.18)
GF Value™: BDT314.14 vs. price of BDT243.60 (22.5% below fair value)
Industry Position: 304.9% above the Drug Manufacturers median (#657 of 734)
No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
76GF Score
Get the complete analysis for DHA:ORIONINFU
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONINFU has been successfully added to your 
